Novartis AG (NVS) on Decifer Markets

Why it ranks here

• Sales are growing about 7% a year, faster than 28 in 100 companies we measure.
• It keeps about 32 cents of every sales dollar as cash, safer than 94 in 100 companies we measure.
• It earns about 16% a year on the money put into the business, better than 75 in 100 companies we measure.

The current read

The evidence on NVS lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full NVS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.